Alethia Young
Stock Analyst at Cantor Fitzgerald
(2.94)
# 1,649
Out of 5,090 analysts
141
Total ratings
54.46%
Success rate
30.69%
Average return
Main Sectors:
Stocks Rated by Alethia Young
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $25.45 | - | 5 | Jul 5, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | n/a | $61.44 | - | 5 | Jun 20, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $800 → $850 | $718.36 | +18.33% | 9 | Oct 16, 2023 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | $18 | $1.42 | +1,167.61% | 6 | Sep 12, 2023 | |
| CRIS Curis | Reiterates: Overweight | $60 | $1.35 | +4,344.44% | 3 | Sep 7, 2023 | |
| ELDN Eledon Pharmaceuticals | Reiterates: Overweight | $9 | $1.58 | +469.62% | 2 | Aug 22, 2023 | |
| VSTM Verastem | Reiterates: Overweight | $34 | $10.36 | +228.19% | 2 | Jul 6, 2023 | |
| BIIB Biogen | Maintains: Neutral | $427 → $327 | $181.30 | +80.36% | 7 | Oct 15, 2021 | |
| ADVM Adverum Biotechnologies | Downgrades: Neutral | $230 → $30 | $4.26 | +604.23% | 4 | Jul 23, 2021 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $408 → $568 | $34.47 | +1,548.05% | 2 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $281 | $455.48 | -38.31% | 5 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $1.54 | +419.48% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $98 | $1.08 | +8,974.07% | 3 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $295 | $329.89 | -10.58% | 9 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $84 → $86 | $121.22 | -29.05% | 3 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $48 | $30.76 | +56.05% | 4 | Oct 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $7.07 | +324.33% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $72 | $27.73 | +159.65% | 8 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $5 | $2.39 | +109.21% | 5 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $83 → $100 | $102.52 | -2.46% | 6 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $185 → $201 | $205.44 | -2.16% | 6 | Apr 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $86 → $85 | $77.26 | +10.03% | 5 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $32 | $15.62 | +104.87% | 1 | Mar 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $211 → $217 | $22.26 | +874.84% | 12 | Feb 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $48 | $44.41 | +8.08% | 4 | Oct 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $17.87 | - | 3 | Mar 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $151 → $154 | $458.12 | -66.38% | 5 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $113 → $116 | $53.40 | +117.23% | 2 | Mar 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $147 → $106 | $5.30 | +1,900.00% | 8 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $28 | $9.61 | +191.36% | 1 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $82 | $177.72 | -53.86% | 2 | Sep 27, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | n/a | $489.31 | - | 1 | Mar 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.80 | - | 1 | Oct 18, 2016 |
Arcus Biosciences
Jul 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $25.45
Upside: -
Arrowhead Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $61.44
Upside: -
Regeneron Pharmaceuticals
Oct 16, 2023
Maintains: Neutral
Price Target: $800 → $850
Current: $718.36
Upside: +18.33%
ALX Oncology Holdings
Sep 12, 2023
Reiterates: Overweight
Price Target: $18
Current: $1.42
Upside: +1,167.61%
Curis
Sep 7, 2023
Reiterates: Overweight
Price Target: $60
Current: $1.35
Upside: +4,344.44%
Eledon Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $9
Current: $1.58
Upside: +469.62%
Verastem
Jul 6, 2023
Reiterates: Overweight
Price Target: $34
Current: $10.36
Upside: +228.19%
Biogen
Oct 15, 2021
Maintains: Neutral
Price Target: $427 → $327
Current: $181.30
Upside: +80.36%
Adverum Biotechnologies
Jul 23, 2021
Downgrades: Neutral
Price Target: $230 → $30
Current: $4.26
Upside: +604.23%
RAPT Therapeutics
Jun 14, 2021
Maintains: Overweight
Price Target: $408 → $568
Current: $34.47
Upside: +1,548.05%
Jun 11, 2021
Maintains: Overweight
Price Target: $285 → $281
Current: $455.48
Upside: -38.31%
Mar 8, 2021
Initiates: Overweight
Price Target: $8
Current: $1.54
Upside: +419.48%
Feb 25, 2021
Maintains: Overweight
Price Target: $86 → $98
Current: $1.08
Upside: +8,974.07%
Feb 3, 2021
Maintains: Overweight
Price Target: $280 → $295
Current: $329.89
Upside: -10.58%
Oct 29, 2020
Reiterates: Overweight
Price Target: $84 → $86
Current: $121.22
Upside: -29.05%
Oct 28, 2020
Maintains: Overweight
Price Target: $30 → $48
Current: $30.76
Upside: +56.05%
Oct 12, 2020
Initiates: Overweight
Price Target: $30
Current: $7.07
Upside: +324.33%
Jul 31, 2020
Maintains: Overweight
Price Target: $70 → $72
Current: $27.73
Upside: +159.65%
Jun 2, 2020
Assumes: Overweight
Price Target: $5
Current: $2.39
Upside: +109.21%
May 19, 2020
Maintains: Neutral
Price Target: $83 → $100
Current: $102.52
Upside: -2.46%
Apr 20, 2020
Reiterates: Overweight
Price Target: $185 → $201
Current: $205.44
Upside: -2.16%
Apr 8, 2020
Reiterates: Overweight
Price Target: $86 → $85
Current: $77.26
Upside: +10.03%
Mar 6, 2020
Maintains: Overweight
Price Target: $30 → $32
Current: $15.62
Upside: +104.87%
Feb 27, 2020
Reiterates: Overweight
Price Target: $211 → $217
Current: $22.26
Upside: +874.84%
Oct 3, 2019
Maintains: Neutral
Price Target: $75 → $48
Current: $44.41
Upside: +8.08%
Mar 22, 2018
Downgrades: Underperform
Price Target: n/a
Current: $17.87
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $151 → $154
Current: $458.12
Upside: -66.38%
Mar 2, 2018
Maintains: Outperform
Price Target: $113 → $116
Current: $53.40
Upside: +117.23%
Jan 24, 2018
Maintains: Outperform
Price Target: $147 → $106
Current: $5.30
Upside: +1,900.00%
Nov 3, 2017
Maintains: Outperform
Price Target: $24 → $28
Current: $9.61
Upside: +191.36%
Sep 27, 2017
Maintains: Neutral
Price Target: $85 → $82
Current: $177.72
Upside: -53.86%
Mar 16, 2017
Initiates: Underperform
Price Target: n/a
Current: $489.31
Upside: -
Oct 18, 2016
Initiates: Outperform
Price Target: n/a
Current: $2.80
Upside: -